Creative Medical Technology Holdings (CELZ) Net Margin (2017 - 2025)
Creative Medical Technology Holdings (CELZ) posted quarterly Net Margin of 74334.93% for Q4 2025, up 2489220.0% year-over-year from N/an in Q4 2024, and down 36.14% quarter-over-quarter from 54603.23% in Q1 2025.
Creative Medical Technology Holdings (CELZ) Net Margin (2017 - 2025) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Net Margin for 9 consecutive years, with 74334.93% the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Margin rose 2489220.0% year-over-year to 74334.93%; the TTM figure through Mar 2026 stood at 203433.4% (down 15191359.0% YoY), while the FY2025 annual figure was 105623.03%, down 4547557.0% from the prior year.
- Net Margin eased to 74334.93% in Q4 2025 per CELZ's latest filing, from 54603.23% in the prior quarter.
- Across five years, Net Margin topped out at 1786.07% in Q3 2022 and bottomed at 99227.13% in Q4 2024.
- Historically, Net Margin has averaged 35327.71% across 5 years, with a median of 26642.18% in 2021.
- Annual changes were most pronounced in 2021 — Net Margin jumped 21536391 bps — and 2024, when it slumped 4327467 bps.
- Creative Medical Technology Holdings' Net Margin stood at 5719.92% in 2021, then tumbled by 484 bps to 33417.7% in 2022, then sank by 67 bps to 55952.47% in 2023, then tumbled by 77 bps to 99227.13% in 2024, then climbed by 25 bps to 74334.93% in 2025.
- Business Quant data shows CELZ's Net Margin at 74334.93% in Q4 2025, 54603.23% in Q1 2025, and 99227.13% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -74,334.93% |
| Mar 31, 2025 | -54,603.23% |
| Dec 31, 2024 | -99,227.13% |
| Jun 30, 2024 | -19,471.60% |
| Dec 31, 2023 | -55,952.47% |
| Sep 30, 2023 | -24,232.53% |
| Dec 31, 2022 | -33,417.70% |
| Sep 30, 2022 | -1,786.07% |
| Mar 31, 2022 | -7,699.13% |
| Dec 31, 2021 | -5,719.92% |
| Sep 30, 2021 | -18,435.96% |
| Jun 30, 2021 | -29,051.82% |
| Dec 31, 2020 | -221,083.82% |
| Sep 30, 2020 | 512.79% |
| Jun 30, 2020 | -6,604.17% |
| Mar 31, 2020 | 8,889.50% |
| Dec 31, 2019 | 117,998.86% |
| Sep 30, 2019 | -4,184.56% |
| Mar 31, 2019 | -1,569.62% |
| Dec 31, 2018 | 3,765.65% |